Program Goals Background: Anticoagulation in Patients With VTE.

Slides:

Advertisements

Similar presentations

Upfront Combination Therapy vs Step-Up Approach for PAH:

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

US Guidelines US Guidelines Low-risk Patients.

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

The ABCs of AF.

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

The Essentials for Secondary Stroke Prevention

Anticoagulation Therapy in Patients Post-TAVR

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Examining the Latest Evidence in PAH

Real-World Evidence in VTE

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Identifying High-Risk AF Patients

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

Factor Xa Inhibitors in PAD

When Is Intrathecal Drug Delivery Appropriate?

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Extraordinary Cases in VTE

Factor Xa Inhibitors in Coronary Artery Disease

The ABCs of AF.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

When Is Intrathecal Drug Delivery Appropriate?

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

My PAH Patient.

Key Data on Improving Outcomes in HF Patients

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Program Goals

Background: Anticoagulation in Patients With VTE

ACCP Clinical Practice Guidelines for Antithrombotic Therapy of VTE

Home vs In-Hospital Treatment of DVT

Practical Advantages of Using NOACs vs Traditional Treatment

Diagnosis of PE

Diagnostic Approaches

Selection of Truly Low-Risk Patients Eligible for Outpatient Treatment

Risk Stratification: Types of Clinical Scores

PESI and sPESI Criteria

Factors to Consider for Home Treatment

NOACs

NOACs Trials: VTE Prevention and Treatments

NOACs: Outcomes From VTE Extension Trials

EINSTEIN-PE Trial: Meta-analysis Based on PESI Score

Hokusai-VTE Study: Analyses Based on NT-proBNP Levels

NOAC Treatment Selection in VTE

Overall Summary

Abbreviations

Abbreviations (cont)